Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes – Advances in treatment

Kristen B. McCullough, Mrinal M. Patnaik

Research output: Contribution to journalReview articlepeer-review


Optimal treatment for myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes remain to be defined and are currently extrapolated from MDS and MPN. The heterogeneity of these diseases and their rare occurrences add to this void. Supportive care therapies such as erythropoiesis stimulating agents, iron chelation and cytoreductive therapy do not have prospective evidence in these disorders and the only approved treatments, hypomethylating agents, are based on the inclusion of a small number of chronic myelomonocytic leukaemia patients in MDS predominant trials. While allogeneic stem cell transplant remains the only curative option, the median age at presentation (7th decade), comorbidities, risk of disease relapse, and transplant related morbidity and mortality, make this option accessible to < 10% of patients. The advent of next generation sequencing has better defined the genomic landscape and opened the doors for personalized medicine. Herein we focus on recent therapeutic advances and options in MDS/MPN overlap syndromes.

Original languageEnglish (US)
Article number101130
JournalBest Practice and Research: Clinical Haematology
Issue number2
StatePublished - Jun 2020


  • Atypical chronic myeloid leukaemia
  • Chronic myelomonocytic leukaemia
  • Myelodysplastic syndrome
  • Myelodysplastic-myeloproliferative diseases

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry


Dive into the research topics of 'Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes – Advances in treatment'. Together they form a unique fingerprint.

Cite this